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Purpose. Diabetic retinopathy (DR) is the leading cause of vision loss among active adults in industrialized countries. We aimed to
investigate the prevalence of diabetes mellitus (DM), DR and its different grades, in patients with DM in the Csongrád County,
South-Eastern region, Hungary. Furthermore, we aimed to detect the risk factors for developing DR and the
diabetology/ophthalmology screening patterns and frequencies, as well as the effect of socioeconomic status- (SES-) related
factors on the health and behavior of DM patients. Methods. A cross-sectional study was conducted on adults (>18 years)
involving handheld fundus camera screening (Smartscope Pro Optomed, Finland) and image assessment using the Spectra DR
software (Health Intelligence, England). Self-completed questionnaires on self-perceived health status (SPHS) and health
behavior, as well as visual acuity, HbA1c level, type of DM, and attendance at healthcare services were also recorded. Results.
787 participants with fundus camera images and full self-administered questionnaires were included in the study; 46.2% of the
images were unassessable. T1D and T2D were present in 13.5% and 86.5% of the participants, respectively. Among the T1D and
T2D patients, 25.0% and 33.5% had DR, respectively. The SES showed significant proportion differences in the T1D group.
Lower education was associated with a lower DR rate compared to non-DR (7.7% vs. 40.5%), while bad/very bad perceived
financial status was associated with significantly higher DR proportion compared to non-DR (63.6% vs. 22.2%). Neither the
SPHS nor the health behavior showed a significant relationship with the disease for both DM groups. Mild nonproliferative
retinopathy without maculopathy (R1M0) was detected in 6% and 23% of the T1D and T2D patients having DR, respectively;
R1 with maculopathy (R1M1) was present in 82% and 66% of the T1D and T2D groups, respectively. Both moderate
nonproliferative retinopathy with maculopathy (R2M1) and active proliferative retinopathy with maculopathy (R3M1) were
detected in 6% and 7% of the T1D and T2D patients having DR, respectively. The level of HbA1c affected the attendance at the
diabetology screening (HbA1c > 7% associated with >50% of all quarter-yearly attendance in DM patients, and with 10% of the
diabetology screening nonattendance). Conclusion. The prevalence of DM and DR in the studied population in Hungary
followed the country trend, with a slightly higher sight-threatening DR than the previously reported national average. SES
appears to affect the DR rate, in particular, for T1D. Although DR screening using handheld cameras seems to be simple and
dynamic, much training and experience, as well as overcoming the issue of decreased optic clarity is needed to achieve a proper
level of image assessability, and in particular, for use in future telemedicine or artificial intelligence screening programs.
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1. Introduction
Diabetes mellitus (DM) is a major medical and societal chal-
lenge due to its rapid increase in global prevalence and devas-
tating late complications [1, 2]. The global occurrence of DM
among adults (>18 years of age) was 8.5% in 2014, and this
has nearly doubled from its 4.7% level in 1980 [3]. In 2016,
1.6 million deaths were directly attributed to DM, with more
than half of them occurring in the lower- and middle-income
countries. According to the WHO forecast, DM will be the
seventh leading cause of death in 2030, while diabetic reti-
nopathy (DR) will be the leading cause of vision loss among
active adults in industrialized countries [4]. DR is the most
common late complication of DM in people aged 20 to 64
years—the working-age population, and except for where
effective screening programs have been implemented, it is
the leading cause of blindness and reduced vision in this
group in the developed world [5, 6]. In a study comparing
data from 35 populations, the global prevalence of sight-
threatening retinopathy (STR) was estimated at 10.2% for all
DM patients [6].
In Hungary, a total of 865 069 patients (9.5% of the pop-
ulation) suffered from DM among adults (>18 years of age)
in 2011 [7], and some degree of DR could be observed among
19% of the patients with type 1 DM (T1D) and 24% in those
suffering from type 2 DM (T2D) for 3 or 4 years [8]. System-
atic DR screening and monitoring has been proven to be
cost-effective in reducing blindness and visual impairment
in patients having DM. Screening enables optimized timing
of laser and medical therapy that may halt disease progres-
sion [9]. The WHO guidelines [10] for DR screening state
that “annual eye examinations are recommended for patients
with diabetes (and every other year for persons with excellent
glycemic control and no retinopathy at the previous exami-
nation...).” “Such programs need systematic evaluation for
their impact on health outcomes, cost effectiveness and
health equity.” The WHO recommendation further states
“Member States should choose the most appropriate interval
between examinations” [10].
The development of optimized and effective DR screen-
ing programs is becoming eminent. The aim of this study
was to investigate the prevalence of DR and its different
grades in patients with DM in the Csongrád County—a
South-Eastern region in Hungary, using for the first time in
this country a handheld fundus camera (Smartscope Pro
Optomed, Finland). Moreover, we aimed to detect the risk
factors for developing DR and the diabetology/ophthalmol-
ogy screening patterns and frequencies, as well as the effect
of socioeconomic status- (SES-) related factors on the health
and behavior of DM patients.
2. Patients and Methods
2.1. Physical Examination. A cross-sectional study was con-
ducted between the Departments of Ophthalmology and
Internal Medicine Diabetology Unit, University of Szeged,
Szeged, Hungary, between November 2015 and December
2016. All examinations were voluntary and free of charge to
the participants, and the patients were recruited consecu-
tively from the Diabetology Outpatient Clinic. Written
informed consent was obtained from all participants. The
study was approved by the local ethical committee of the
University of Szeged (No.197/2015). The detection of DR
was based upon examination with a handheld fundus camera
(Smartscope Pro Optomed, Finland) in a dark room by qual-
ified professionals. The results were directly evaluated by a
qualified specialist without the need to do data/file transfer.
In the case of constricted pupil, another image was taken
after ensuring normal intraocular pressure level and applying
cyclopentolate (5mg/mL) eye drops to achieve mydriasis.
The assessment of the fundus images was performed using
the Spectra DR software (Health Intelligence, UK). The
recordings were safely deposited and kept inaccessible to
third parties for 10 years at a designated server, so that later
they can be used in further comparative studies on DR.
The images acquired with the Optomed Smartscope Pro
digital handheld camera included two pictures from the par-
ticipants’ eyes—one with the macula—and another with the
optic nerve—in the center—which is in line with the English
screening requirements [11]. In case of presence of ambly-
opia or nontransparent media (e.g., cataract and corneal or
visual axis obstructing conditions), the patients were
excluded from the study. During image evaluation, the
graders (A.F./G.P./G.R.) classified the signs and stages of
DR and maculopathy in the standardized English-based soft-
ware Spectra DR and graded the images in alignment with
the English standard grading protocols [12]. Each image
was evaluated in two stages: first, the referral outcome
graders/ROGs (D.E./G.R.) evaluated them, and then a super-
visor/ophthalmic consultant confirmed the diagnosis
(A.F./G.P.). At the end, an expert opinion regarding the
grade of retinopathy was provided, which included the stage
of retinopathy (R0/1/2/3A) and the absence or existence of
maculopathy (M0/1). Other discovered abnormalities were
not diagnosed in this study, although they were recorded,
as they can provide further information about other symp-
toms, which may have occurred in the past, and therefore
may require medical attention over a specified period of time.
The classification of the DR has been described before
[13]—in brief: (R0) no clinical anomaly—repeated screen-
ing was recommended one year later; (R1) mild nonproli-
ferative—presence of microaneurysms, dot- or blot- like
hemorrhages, or exudates—control examination was rec-
ommended one year later; (R2) moderate or severe nonpro-
liferative—presence of major bleeding(s) and intraretinal
microvascular abnormalities (IRMAs)—control examina-
tion was required within one month; (R3A) active prolifer-
ative—presence of neovascularization of the optic disc
(NVD) or elsewhere (NVE) or preretinal bleeding(s), vitre-
ous bleeding, preretinal fibrosis, and tractional retinal
detachment—immediate medical examination was required
within two weeks. All the stages were combined with sight-
threatening maculopathy which was determined by the pres-
ence of exudates regardless of visual acuity (VA), or red
lesions with a VA of 6/12 or worse after pinhole correction,
that is within 1 disc diameter of the center of the fovea,
and/or a group of exudates where the area of exudates that
is greater than or equal to half the disc area, and this area is
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all within the macular area (as defined by the ETDRS macu-
lar grid) when medical examination was required within a
month (M1).
2.2. Self-Completed Questionnaire. Participants were asked to
fill out a self-administered questionnaire which was based
upon the European Health Interview Survey 2009—it
included demographic characteristics such as gender, age,
and place of residency. From the place of residency, the
distance to the healthcare facility was calculated as <10 km
or ≥10 km.
The marital status was categorized as married or lives
with a partner, single, separated or divorced and widowed;
due to the low sample size, categories were merged together
as living alone or living in partnership. SES of the study par-
ticipants was examined: education and economic status. The
economic status was characterized as working—full time
and working—part-time, unemployed, retired, temporarily
laid off, and student; due to the lack of data between each
category, the categories were allocated and merged as
inactive or active. The level of education was measured as
primary, secondary, or higher education (college, university,
or higher).
Data were collected about self-perceived health status
(SPHS) and characterized as bad satisfactory, and good.
Information was also collected about “Perception of what
the subject can do for his/her health status,” and the informa-
tion was categorized as almost nothing (nothing/little) or
much more (much/very much).
Health behavior was assessed by alcohol consumption,
smoking, physical activity, and diet (no/yes). Smoking was
classified as yes/quit/never smoking, while alcohol consump-
tion was classified as no/yes. Physical activity was defined
according to the amount or occasions spent in the previous
month in cycling, walking: daily/weekly more time, weekly,
once/no activity at all (inactive).
Information was also collected about the DM-related and
other health conditions, for example, if the study participant
has/had hypertension: no/yes. If yes, data were collected
about the duration of the hypertension (years). If the partic-
ipant attended blood pressure controls, a recording was made
about the last measurement of the systolic and diastolic blood
pressures in millimeters of mercury (mmHg).
Information was further collected about other health
conditions, for example, VA (<0.3 or ≥0.3), HbA1c level
(normal <7% or elevated ≥7%), type of diabetes mellitus
(T1DM or T2DM), use of medications, DM in the family or
occurrence of diabetic maculopathy. In addition, data about
the attendance at healthcare services like diabetology
(monthly, every 3rd month, every 6th month, yearly, more
than a year, or no attendance) were also collected.
2.3. Statistical Analysis. The analysis of the data was per-
formed by descriptive statistics; percentage distribution,
mean and standard deviation (SD), and in case of nonnorm-
ality of continuous variables, median and interquartile range
(IQR) and range (minimum, maximum) are shown. Normal-
ity of the continuous variables was tested on a histogram, Q-
Q- plot, and by Shapiro-Wilk and Kolmogorov-Smirnov test.
The Independent Sample T-test was used to compare the
means of the continuous, numerical variables, when the nor-
mality assumption was satisfied; otherwise, Mann–Whitney
U test was used. Homogeneity of variance was analyzed with
the Levene test.
Chi-square (χ2) and Fisher test were used to test the
differences of the distribution of categorical variables; for
multiple comparisons, the 2-sample z-test with Bonferroni
correction was applied to detect the differences in the propor-
tions between the studied groups. If the sample within each
column was 1 or less, then the z-test could not be used. The
significance limit was set at P < 0:05. The statistical analysis
of the data was performed by IBM SPSS Statistics Version
24 software.
2.4. Ethical Issues. The Regional and Institutional Human
Medical Biological Research Ethics Committee of the Szent-
Györgyi Albert Clinical Center, University of Szeged
approved the study protocol (No. 197/2015). The research
provided anonymity to the participants. Before the beginning
of a test, the participants signed a voluntary written consent
form in which they agreed to permit the use of data for
research purposes.
3. Results
The data were collected from a total of 848 participants with
known DM in the Csongrád County, South-Eastern region in
Hungary (Figure 1). Out of the initial participants, 787
(92.8%) had available fundus camera images and answered
the self-administered questionnaire. T1D was present in
13.5% (N = 52) of participants, while T2D was present in
86.5% (N = 334) of the participants. Among the T1D and
T2D patients, 25.0% (N = 13) and 33.5% (N = 112) had DR,
respectively. A large portion of the participants had unasses-
sable fundus camera images/results 46.2% (N = 363) when
using the handheld camera, and therefore excluded from
the further analysis (Figure 1).
The data analysis was based upon the remaining 386
individuals, who had assessable fundus camera images and
possessed complete data about the type of diabetes and the
risk parameters studied.
Table 1 shows the characteristics of the studied partici-
pants. Gender, age, and marital status showed no significant
proportion differences between the study groups, while SES
showed significant proportion differences in the T1D group.
The proportion of the DR differed significantly in the Educa-
tion and Perceived Financial Status groups, and it was signif-
icantly higher among those with higher education
(secondary/higher being 61.5%/30.8%) and perceived bad
financial status (63.6%). The distance travelled to the health-
care service showed a nearly significant association with the
DR—participants living more than 10 km away from the
healthcare services had a higher proportion of DR (61.5%).
Tables 2 and 3 show the results of the SPHS and the
health behavior of the individuals, neither of which showed
a significant relationship with the disease for both, T1D and
T2D groups.
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Table 4 shows the characteristics of the health status of
the study participants. A significant difference was only pres-
ent in case of diabetes medication use and presence of dia-
betic maculopathy in T2D patients having DR and non-DR,
with the rest of the parameters included (hypertension, VA,
HbA1c, duration of DM, and familiar presence of DM)
showing no significant proportion differences between the
studied groups.
Mild nonproliferative retinopathy without maculopathy
(R1M0) was detected in 6% of the T1D patients having DR,
and 23% of the T2D patients having DR. Among the patients
having DR, R1 with maculopathy (R1M1) was present in 82%
of the T1D group, and 66% of the T2D group. Both moderate
nonproliferative retinopathy with maculopathy (R2M1) and
active proliferative retinopathy with maculopathy (R3M1)
were detected in 6% of the T1D patients having DR. Among
the T2D patients having DR, the prevalence of R2M1 was 4%,
while the prevalence of R3M1 was 7% (Figure 2).
The level of HbA1c affected the participation in the diabe-
tology screening, with those havingHbA1c > 7% representing
more than 50% of all quarter yearly attendance for both types
of DM (Figure 3). About 10% of the population had no diabe-
tology screening attendance for those havingHbA1c > 7% for
both types ofDMandHbAc < 7%T2D. For both types ofDM,
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Figure 1: Flowchart of the study sample. DR: diabetic retinopathy; Non-DR: nondiabetic retinopathy; N: number. ∗Fulfilled the self-
completed questionnaire and had a fundus camera image taken.
Table 1: Characteristics of the study sample.
T1D N = 52 (%) T2D N = 334 (%)
DR N = 13 (%) Non-DR N = 39 (%) DR N = 112 (%) Non-DR N = 222 (%)
Gender
Male 7 (53.8) 23 (59.0) 47 (42.0) 94 (42.3)
Female 6 (46.2) 16 (41.0) 65 (58.0) 128 (57.7)
Age (mean ± SD) 70:8 ± 6:0 66:4 ± 12:2 66:4 ± 12:8 65:7 ± 13:0
Distance to the healthcare services
<10 km 5 (38.5) 27 (69.2) 75 (67.0) 140 (63.4)
≥10 km 8 (61.5) 12 (30.8) 37 (33.0) 81 (36.6)a
Education
Primary 1 (7.7) 15 (40.5) 54 (48.2) 94 (43.5)
Secondary 8 (61.5) 10 (11.2) 30 (26.8) 79 (36.6)
Higher 4 (30.8) 12 (32.4) 28 (25.0) 43 (19.9)b
Perceived financial status
Bad 7 (63.6) 8 (22.2) 24 (23.1) 58 (27.6)
Satisfactory 2 (18.2) 23 (63.9) 70 (67.3) 131 (62.4)
Good 2 (18.2) 5 (13.9) 10 (9.6) 21 (10.0)c
Marital status
Living alone 1 (7.7) 5 (13.9) 37 (33.0) 60 (27.8)
Living in partnership 12 (92.3) 31 (86.1) 75 (67.0) 156 (72.2)d
Economic status
Active 9 (69.2) 21 (55.3) 21 (18.7) 63 (28.9)
P < 0:05. T1D: type 1 diabetes mellitus; T2D: type 2 diabetes mellitus; DR: diabetic retinopathy; Non-DR: nondiabetic retinopathy; N : number; SD: standard
deviation. Missing data: (a) 1; (b) 8; (c) 25; (d) 7.
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the yearly attendance was below 5%, while more than yearly
attendance was absent for all studied groups, and low for
T2D patients having HbA1c > 7% (Figure 3).
4. Discussion
DR is the most common late complication of DM in the
working-age population and the leading cause of blindness
in the elderly, accounting for a significant drop in the quality
of life (QoL) and working ability for the patients [5, 14]. In a
study comparing data from 35 populations, the global preva-
lence of sight-threatening retinopathy (STDR) was estimated
to 10.2% for all DM patients [6]. Our study found high rates
of R2M1 and R3M1, moderate and active proliferative reti-
nopathy (6% and 7% for T1D and T2D, respectively), which
is similar to the world average found so far.
A previous study in Hungary found the prevalence rate of
DM in participants aged 20-69 years to be 7.47% [15]. More
recently, a study from Hungary showed 24.5% of all incident
DM cases to be T2D [16]. The same study also showed T1D
to be the most common form of DM in children and adoles-
cents, with its frequency having a tendency of continuous
rising, while the occurrence of medically treated cases of
T2D not to be increasing. The prevalence of T2D, however,
is increasing due to an obesity epidemic and aging of the pop-
ulation, hence, one may expect a dramatic increase in DM
during the next decades [1, 2, 10]. In the Csongrád County,
South-Eastern region of Hungary, the studied cohort showed
an approximate 1 : 7 ratio of T1D :T2D cases.
The population in the Csongrád County in Hungary is
characterized by significant SES differences, and these appear
to reflect upon significant proportion differences, in particu-
lar, in the T1D population. It has been previously reported
that poorer populations having Medicaid insurance in the
U.S. are associated with worse DR follow-up in predomi-
nantly rural patients [17]; this population appears to be
similar to the rural population in the Csongrád County,
Hungary. A statistically significant relationship between
Table 2: Self-perceived health status of the study sample.
T1D N = 52 T2D N = 334
DR N = 13 (%) Non-DR N = 39 (%) DR N = 112 (%) Non-DR N = 222 (%)
Self -perceived health
Bad 2 (15.4) 7 (18.4) 28 (25.2) 65 (29.3)
Satisfactory 7 (53.8) 24 (63.2) 64 (57.7) 135 (60.8)
Good 4 (30.8) 7 (18.4) 19 (17.1) 22 (9.9)a
What the person can do for his/her health
Very much/much 10 (83.3) 30 (78.9) 91 (82.0) 167 (76.6)
Little/nothing 2 (16.7) 8 (21.1) 20 (18.0) 51 (23.4)b
P < 0:05. T1D: type 1 diabetes mellitus; T2D: type 2 diabetes mellitus; DR: diabetic retinopathy; Non-DR: nondiabetic retinopathy;N : number. Missing data: (a)
2; (b) 7.
Table 3: Health behavior of the study participants.
T1D N = 52 T2D N = 334
DR N = 13 (%) Non-DR N = 39 (%) DR N = 112 (%) Non-DR N = 222 (%)
Physical activity in the last month
Every day/more times a week 6 (46.1) 26 (66.7) 61 (57.0) 118 (55.9)
Weekly 5 (38.5) 6 (15.4) 17 (15.9) 40 (19.0)
Only once in the last month/inactive 2 (15.4) 7 (17.9) 29 (27.1) 53 (25.1)a
Diet
Yes 13 (100.0) 35 (92.1) 85 (77.3) 175 (81.8)
No 0 (0.0) 3 (7.9) 25 (22.7) 39 (18.2)b
Smoking
Yes 5 (41.7) 6 (16.2) 8 (7.3) 21 (9.8)
Quit 2 (16.6) 8 (21.6) 38 (34.9) 74 (34.4)
Never 5 (41.7) 23 (62.2) 63 (57.8) 120 (55.8)c
Alcohol consumption
Yes 7 (53.8) 11 (28.9) 35 (32.4) 79 (36.6)
No 6 (46.2) 27 (71.1) 73 (67.6) 137 (63.4)d
P < 0:05. T1D: type 1 diabetes mellitus; T2D: type 2 diabetes mellitus; DR: diabetic retinopathy; Non-DR: nondiabetic retinopathy;N : number. Missing data: (a)
16; (b) 11; (c) 13; (d) 11.
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diabetes complications, age group, educational level, job
status, relationship with family members, number of family
visits, and the reassurance provided by the family, type of
leisure activities, health status, years with diabetes, smoking,
type of treatment, fried food consumption and income, sense
of security and communication in living environment, and
daily intake of vegetables, has also been reported in a study
cohort of T2D patients [18]. Furthermore, no statistical inter-
action could be found between SPHS and gender, while
reporting the self-perceived health as poor has been associ-
ated with higher reporting of chronic diseases, including
diabetes [19].
Although hypertension, VA, HbA1c, duration of DM,
and familiar presence of DM showed no significant difference
in our study, another study on a population having T2D
found a statistically significant difference between SPHS
and the levels of HbA1c; the latter study also showed age,
level of education, mode of treatment, adherence to treat-
ment, and level of exercise to be factors having statistically
significant differences from, and therefore an influence on,
self-reported health in a single province in Turkey [20].
Patients with T1D have been shown to have a faster decrease
in the perceived health and functioning over time compared
to aged persons from the general population [21].
The distribution of the DR showed similar retinopathy
with maculopathy (R1M1) presence (82% in the T1D group
and 66% in the T2D group) compared to an English study
on both DR types (89% had a diagnosis of R1M1 in one eye
in those screened positive for maculopathy (M1) in at least
one eye) [22]. Our handheld camera produced unassessable
fundus image results in nearly half of the participants when
used by newly trained image acquisition staff (DJE and
DJS); however, in an older population having T2D, this can
also be due to the presence of optic axis opacities such as
Table 4: Characteristics of the health status of the study participants.
T1D N = 52 T2D N = 334
DR N = 13 (%) Non-DR N = 39 (%) DR N = 112 (%) Non-DR N = 222 (%)
Hypertension 4 (30.8) 21 (55.3) 97 (87.4) 190 (88.4)
Systolic blood pressure (median, IQR, range)
153 (133-162) 135 (129-150) 130 (122-140) 130 (123-140)
120-191 120-158 105-189 100-169
Diastolic blood pressure (mmHg) (median, IQR, range)
84 (80-85) 80 (70-85) 80 (75-85) 80 (70-85)
78-95 58-90 60-104 60-101
Duration of hypertension (year) (median, IQR, range)
18 (3-42) 11 (7-20) 20 (10-40) 20 (10-37)
3-52 2-53 2-56 3-56
Visual acuity
<0.3 0 (0.0) 0 (0.0) 6 (16.7) 2 (5.5)
≥0.3 3 (100.0) 2 (100.0) 30 (83.3) 38 (95.0)a
HbA1c
Elevated (≥7%) 13 (100.0) 37 (93.4) 88 (82.2) 170 (79.4)
Duration of diabetes (median, IQR, range)
20 (14-24) 20 (13-27) 13 (8-20) 15 (8-20)
10-38 1-60 0-38 0-40
Diabetes medication 5 (41.7) 13 (34.2) 86 (77.5) 187 (86.6)
Diabetes in the family 6 (46.1) 21 (53.8) 52 (46.8) 124 (56.6)
Diabetic maculopathy 7 (53.8) 2 (5.1) 81 (73.6) 15 (6.8)
P < 0:05. T1D: type 1 diabetes mellitus; T2D: type 2 diabetes mellitus; DR: diabetic retinopathy; Non-DR: nondiabetic retinopathy; N : number; IQR:










Figure 2: Distribution of the diabetic retinopathy according to the type of diabetes mellitus. DM: diabetes mellitus; T1D and T2D: type 1 and
2 DM.
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cataract and vitreous hemorrhage. In our study, 6% and 7%
of the T1D and T2D population, respectively, had R3M1
(proliferative diabetic retinopathy with maculopathy), while
6% and 4% of the T1D and T2D population, respectively,
had R2M1 (preproliferative diabetic retinopathy with macu-
lopathy); therefore, a total of 23% of the population had
higher chance for DM-associated cataracts and or vitreous
hemorrhages, as well as poor fixation due to macular edema.
A limitation of our study is the fact that such changes were
not recorded at the time the screening was conducted. Other
studies have, however, shown that such handheld cameras
can provide comparable results to standard fundus cameras
[23]. Later versions of this camera (The Optomed Aurora)
appear to have a built-in instant quality feedback software
that aids the photographer to gain information when the
image is assessable. In the latter study, the two cameras used
reached high agreement on the diagnosis of retinopathy and
maculopathy at all the levels of retinopathy. Sufficient train-
ing of paraprofessional health care staff can lead to obtaining
higher quality images with a portable nonmydriatic fundus
camera [24]. Known risk factors for developing DR are age,
gender, duration and type of DM, elevated HbA1c, high
blood pressure, and retinopathy stage, while other risk
factors are being investigated. DR is caused by damage to
the retinal microvasculature. Proper screening for DR is an
important milestone towards achieving early and efficient
treatment for preventing visual loss [9]. For optimal effect,
laser treatment must be applied as early as possible after the
formation of new pathological retinal vessels, at which time
most patients are asymptomatic. In addition, antivascular
endothelial growth factor (VEGF) drugs or steroids injected
into the vitreous of the eye may reduce diabetic macular
edema [25, 26]. Other European countries like Iceland,
Denmark, Sweden, and England have successfully imple-
mented nationwide DR screening programs. In Iceland,
diabetic blindness prevalence has decreased 4-5 fold after
the introduction of systematic DR screening, and a similar
success rate has been observed in Denmark [27].
Hungary, at present, has no coordinated national screen-
ing program for DR, despite the clear need and high number
of patients with DM. Furthermore, in many parts of the
country, there are no clear communication channels between
GPs, diabetologists, and ophthalmologists regarding screen-
ing and sharing results from a DR assessment. Today, a
newly diagnosed DM patient must be actively referred for
an eye examination by his/her GP or endocrinologist, and
often the patient her-/himself must book the appointment.
In addition, the interval between eye examinations is at the
ophthalmologist’s discretion. A standardized rapid assess-
ment of avoidable blindness (RAAB) with the DR module
(DRM) has recently been used in Hungary in people aged
50 years and older: 20.0% of the 3523 participants had a
known or newly diagnosed DM; 20% of the participants with
known DM had a blood glucose level of ≥200mg/dL; and
27.4% had never had an ophthalmological examination for
DR. The prevalence of DR and/or maculopathy was found
to be 20.7%, while the prevalence of STDR was 4.3% in one
or both eyes among the participants with DM in Hungary
[28]. This finding is lower than the one determined in the
Csongrád County in Hungary, which can certainly underline
disparities in the DR grading standards used or the distribu-
tional difference of DR throughout the different counties in
the country.
A systematic DR screening in the Csongrád County,
South-Eastern region in Hungary, could have significantly
reduced the total load of ophthalmologist exams, and thus
increase the overall capacity in ophthalmology—a field with
vast capacity challenges [19]. More importantly, the lack of
systematic DR screening also puts patients with a high risk
of eye disease progression at an even higher risk, as they are
not receiving the regular follow-up examinations needed.
The WHO guidelines for DR screening [5, 14] recommend
annual eye examinations for patients with diabetes and bien-
nially for persons with excellent glycemic control and no
retinopathy at the previous examination. The International
Council for Ophthalmology (ICO) now recommends bien-
nial screening for DM patients without retinopathy. In
general, there is a low annual incidence of STR, and 97% of
the screening visits do not lead to any active treatment [29].
However, with the increasing prevalence of DM, especially
T2D, and limited eye care capacity, advocating for a person-
alized health care approach towards patient-tailored screen-
ing and recommendation for each individual patient has
been proposed.
In Iceland for example, a path of improving cost-efficacy
of screening systems has been chosen by reducing the num-
ber of unnecessary screening visits. Based on a biennial
screening model, the following risk variables have been
included to improve risk predictions for each individual
patient: age, gender, diabetes duration, type of diabetes,
HbA1c level, blood pressure, and retinopathy stage. An Euro-
pean collaborative network has used this model to calculate




















Figure 3: Attendance rate in the diabetology screening among those
with normal or elevated HbA1c. T1D: type 1 diabetes mellitus; T2D:
type 2 diabetes mellitus. ∗Data presented are based upon the result
of 1 individual in case of the T1D group having HbA1c <7%.
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patient, the outcome of which was a reduction of 17-23% in
the screening visits needed, compared to the biennial screen-
ing model [29, 30]. A personalized screening approach would
have the advantage of recommending more frequent screen-
ing intervals to high-risk patients and less frequent to low-
risk patients. The risk variable profile also shows significant
alterations between different countries and also between
different ethnic- and socioeconomic populations within the
same country and region, thus, the one-size-fits-all approach
may not be the best for diverse populations globally.
In conclusion, this study in the Csongrád County, South-
Eastern region, Hungary, determined the prevalence of DM
and DR, which appeared to follow the country trend, except
for the slightly higher STDR. SES appears to affect the DR
rate, in particular, for T1D. The DR screening using the
Smartscope Pro Optomed handheld camera, although simple
and dynamic, requires much training and experience to
achieve proper levels of image assessability if future use in
telemedicine or artificial intelligence screening programs or
personalized medicine is planned.
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Data from this study are available on request through the
corresponding author.
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